Skip to main content
SpringerLink
Log in

Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Topotecan is a topoisomerase (topo) I inhibitor with promising activity in preclinical studies. We hypothesized that low-dose intratumoral delivery of topotecan would be highly effective for gliomas. Human glioma cell lines (U87, U138 and U373) displayed different sensitivities to topotecan (IC50 range: 0.037 μM to 0.280 μM) in cell culture. The most resistant of the glioma cell lines (U87) was implanted stereotactically into the brains of nude rats. Twelve days later, at which time tumor diameter measured 2 to 2.5 mm, animals were randomized to three groups: group I, intratumoral topotecan infused via osmotic pump (n = 12); group II, intratumoral saline infusion (n = 7); and group III, no treatment (n = 10). Animals were sacrificed when signs of deterioration developed, or at 60 days. Animals in group I had a mean survival time (MST) of > 55 days (range=40–60); whereas, those in groups II and III had MST of 26.1 (range=21–31) and 26.5 (range = 20–30) days, respectively. The differences in survival between group I and each of the other groups were statistically significant (p < 0.0001; Logrank Mantel-Cox). None of the animals that survived 60 days had histological evidence of residual tumor at sacrifice. Measurement of topotecan levels in normal brain revealed cytotoxic concentrations up to 4.5 mm from the site of infusion. This study demonstrates that intratumoral topotecan delivered via an osmotic pump prolongs survival in the U87 human glioma model.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Burris HA III, Fields SM: Topoisomerase I inhibitors. An overview of the camptothecin analogs. Hematol/Oncol Clin N AM 8(2): 333–355, 1994

    Google Scholar 

  2. Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK, Hertzberg RP: Synthesis of water soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98–107, 1991

    Google Scholar 

  3. Slichenmcyer WJ, Rowinsky EK, Donchower RC, Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85(4): 271–291, 1993

    Google Scholar 

  4. Chen AY, Liu LF: DNA topoisomerases, essential enzymes and lethal targets. Ann Rev Pharmacol Toxicol 34: 191–128, 1994

    Google Scholar 

  5. Eng W-K, Faucette L, Johnson RK, Sternglanz R: Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34: 755–760, 1988

    Google Scholar 

  6. Hsiang Y-H, Lihou GM, Liu LF: Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077–5082, 1989

    Google Scholar 

  7. Burris HA III, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, Von Hoff DD: Activity of topotecan, a new topoisomerase inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 84: 1816–1820, 1992

    Google Scholar 

  8. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA: Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31(3): 229–239, 1992

    Google Scholar 

  9. Cheson BD, Phillips PH, Arbuck SG: Clinical trials: trials of topotecan. Oncol 9(3): 220–228, 1995

    Google Scholar 

  10. Macdonald D, Cairncross G, Stewart D, Forsyth P, Sawaka C, Wainman N, Eisenhauer E: Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann Oncol 7(2): 205–207, 1996

    Google Scholar 

  11. Burris HA, Rothenburg ML, Kuhn JG, Von Hoff DD: Clinical trials with topoisomerase I inhibitors. Semin Oncol 19(6): 663–669, 1992

    Google Scholar 

  12. Murphy B, Saltz L, Sirott M, Young C, Tong W, Trochanowski B, Toomasi F, Kelsen D: Granylocyte colony stimulating factor (G-CSF) does not increase the maximum tolerated dose (MTD) in a phase I study of topotecan. Proc Am Soc Clin Oncol 11: 139, 1992 (abstr)

    Google Scholar 

  13. Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG: Plasma and CSF pharmacokinetic study of topotecan in non-human primates. Cancer Res 53: 725–727, 1993

    Google Scholar 

  14. Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurol 30: 908–911, 1980

    Google Scholar 

  15. Beidler DR, Cheng YC: Camptothecin induction of a time-and concentration-dependent decrease of topoisomerase I and its implantation in camptothecin activity. Mol Pharmacol 47: 907–914, 1995

    Google Scholar 

  16. Walter KA, Tamargo RJ, Olivi A, Burger PC, Brem H: Intratumoral Chemotherapy. Neurosurg 37(6): 1129–1145, 1995

    Google Scholar 

  17. Brem H, Mahaley MS Jr, Vick NA, Black KL, Schold SC, Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74: 441–446, 1991

    Google Scholar 

  18. Brem H, Piantadosi S, Burger PC: Intraoperative chemotherapy using biodegradable polymers: safety and effectiveness for recurrent glioma evaluated by a prospective, multi-institutional placebo-controlled clinical trial. Lancet 345: 1008–1012, 1995

    Google Scholar 

  19. Brem H: Polymers to treat brain tumors. Biomaterials 11: 699–701, 1990

    Google Scholar 

  20. Langer R, Brem H, Langer LF: New directions in CNS drug delivery. Neurobiol Aging 10: 642–644, 1989

    Google Scholar 

  21. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: Ne colorimetric assay for anticancer-drug screening. JNCI 82(13): 1107–1112, 1990

    Google Scholar 

  22. Perez RP, Godwin AK, Handel LM, Hamilton TC: A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur J Cancer 29A(3): 395–399, 1993

    Google Scholar 

  23. Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroy P, de Leon CG, Kim EE, Madden T, Wallin B, Hord M, Verschraegen C, Raber M, Kavanagh JJ: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14(5): 1552–1557, 1996

    Google Scholar 

  24. Pratesi G, Tortoreto M, Corti C, Giardini R, Zanino F: Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. Br J Cancer 71: 525–528, 1995

    Google Scholar 

  25. Blaney SM, Cole DE, Godwin K, Sung C, Poplack DG, Balis F: Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol 36: 121–124, 1995

    Google Scholar 

  26. Sung C, Blancy SM, Cole DE, Balis FM, Dedrick RL: A pharmacokinetic model of topotecanclearance from plasma and cerebrospinal fluid. Cancer Res 54: 5118–5122, 1994

    Google Scholar 

  27. Blasberg RG, Patlak C, Fenstermacher JD: Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195: 73–83, 1975

    Google Scholar 

  28. Fenstermacher JD, Kaye T: Drug 'diffusion’ within the brain. Ann NY Acad Sci 531: 29–39, 1988

    Google Scholar 

  29. Langer R, Folkman J: Polymers for sustained release of proteins and other macromolecules. Nature 263: 797–800, 1976

    Google Scholar 

  30. Langer R: New methods of drug delivery. Science 249: 1527–1533, 1990

    Google Scholar 

  31. Lum J, Nguyen T, Felpel L: Drug distribution in solid tissue of the brain following chronic local perfusion utilizing implanted osmotic minipumps. J Pharm Meth 12: 141–147, 1984

    Google Scholar 

  32. Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL: High flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol 266: R292–R305, 1994

    Google Scholar 

  33. Bobo H, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci 91: 2076–2080, 1994

    Google Scholar 

  34. Lieberman DL, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH: Convection enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82: 1021–1029, 1995

    Google Scholar 

  35. Weingart JD, Thompson RC, Tyler B, Colvin OM, Brem H: Local delivery of the topoisomerase inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int J Cancer 62: 605–609, 1995

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, S.U.N.Y. at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York, USA

    John Pollina, Robert J. Plunkett & Robert A. Fenstermaker

  2. Laboratory of Cellular Implantation and Regeneration, Buffalo Veteran's Affairs Medical Center, Buffalo, New York, USA

    John Pollina, Robert J. Plunkett, Agnieszka Lis & Tara A. Barone

  3. Roswell Park Cancer Institute, Buffalo, New York, USA

    Robert J. Plunkett, Michael J. Ciesielski, Tara A. Barone, Steven J. Greenberg & Robert A. Fenstermaker

Authors
  1. John Pollina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert J. Plunkett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael J. Ciesielski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Agnieszka Lis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tara A. Barone
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Steven J. Greenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Robert A. Fenstermaker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pollina, J., Plunkett, R.J., Ciesielski, M.J. et al. Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model. J Neurooncol 39, 217–225 (1998). https://doi.org/10.1023/A:1005954121521

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005954121521

Search

Navigation